Navigation Links
Vanda Pharmaceuticals, Inc. Sued by Investor

SAN DIEGO and WASHINGTON, July 3, 2013 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP announce that a shareholder of Vanda Pharmaceuticals, Inc. (NasdaqGM: VNDA) securities has filed a complaint in the U.S. District Court for the District of Columbia against the company and certain of its officers and directors.  The complaint alleges that defendants violated the Securities Exchange Act of 1934 between December 18, 2012 and June 18, 2013 (the "Class Period").


Vanda is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  The company's product portfolio includes tasimelteon, which is currently in clinical development for "Non-24," a neurological sleep disorder that affects proportionately more totally blind individuals than sighted.

Vanda Is Accused of Making False and Misleading Statements Regarding Results of Its Clinical Trial for Tasimelteon

Throughout the Class Period, defendants made false and/or misleading statements and failed to disclose material adverse facts about the results of the clinical trial for tasimelteon.  Specifically, defendants made false and/or misleading statements and failed to disclose that: (i) the company made multiple changes in the primary endpoint over the course of the trials; (ii) the company eliminated nighttime total sleep as the primary endpoint in its studies as there was no discernible difference in efficacy and safety in nighttime total sleep between those patients deemed to have Non-24 and those patients with a normal sleep cycle; and (iii) the company made a change in a new primary endpoint just one month before study results were published that has allegedly never been used before in sleep-drug clinical trials, nor was it endorsed by the U.S. Federal Drug Administration.

Vanda Stock Price Falls Dramatically on Question of Validity of Clinic Trial for Tasimelteon

On June 19, 2013, The Street published an article casting doubt on the quality and efficacy of Vanda's clinical trial procedure and test data for tasimelteon.  In addition to the issues listed above, the article states that Vanda was forced to cut patient enrollment in the clinical trials in half because an insufficient number of totally blind patients with Non-24 could not be identified, and that ultimately less than 5% of the patients enrolled in the trials suffered from Non-24 according to the "textbook definition" of the disease.

On this news, Vanda shares declined $2.41 per share or more than 22%, to close at $8.51 per share on June 19, 2013.

If you invested in Vanda and would like to discuss your shareholder rights, please contact attorney Darnell R. Donahue at (800) 350-6003,, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law.  The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.  For more information, please go to

Press release link:

Attorney Advertising. Past results do not guarantee a similar outcome.  

Darnell R. Donahue
Robbins Arroyo LLP
(619) 525-3990 or Toll Free at (800) 350-6003

SOURCE Robbins Arroyo LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals Reports First Quarter 2012 Results
2. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
3. Vanda Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
4. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
5. Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
6. Vanda Pharmaceuticals to Present at the JMP Securities Healthcare Conference
7. Vanda Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 2, 2012
8. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
9. Vanda Pharmaceuticals Reports Third Quarter 2012 Results
10. Vanda Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on February 12, 2013
11. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
Post Your Comments:
(Date:11/24/2015)... 2015  DILON Diagnostics and GE Healthcare are pleased ... DILON to distribute GE,s Discovery NM750b Molecular Breast Imaging ... this distribution agreement will provide Dilon,s experienced distribution network ... and is considered an initial step in an ongoing ... clinicians and their patients. --> ...
(Date:11/24/2015)... November 24, 2015 Sectra (STO: ... has entered into a multi-year agreement to deploy ... investment will provide the Breast Center a future-proof platform ... (STO: SECT B) announces that Breast Center of ... deploy Breast Imaging PACS in its two freestanding imaging ...
(Date:11/24/2015)... FRAMINGHAM, Mass. , Nov. 24, 2015   ... leading innovator of less-invasive, miniaturized circulatory support technologies that ... announced that President and Chief Executive Officer Doug ... Jaffray 27 th Annual Healthcare Conference on December ... being held December 1-2 in New York ...
Breaking Medicine Technology:
(Date:11/25/2015)... WASHINGTON, D.C. (PRWEB) , ... November 25, 2015 , ... ... driving fatalities on our nation’s roadways has dropped below 10,000 for the first time ... to 10,076 in 2013. , According to data released by the National Highway Traffic ...
(Date:11/25/2015)... ... November 25, 2015 , ... An ... is resulting in a way for homeless people to have a more dignified ... a new initiative whereby they are repurposing plastic bags into sleeping mats for ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... offering lower prices in an early celebration of the early holiday shopping season. ... of $29.95 each (normally $33.95 ea). Black Friday promotional pricing is in addition ...
(Date:11/24/2015)... ... November 24, 2015 , ... Young patients with a ... Dr. Angela Wolfman and Dr. Kedar S. Lele, who are pediatric dentists in ... and fillings, the WaterLase iPlus 2.0™ system causes minimal discomfort and bleeding to the ...
(Date:11/24/2015)... ... 24, 2015 , ... DMG Productions announced that they will feature Aphria, Inc., ... via Discovery Channel. Dates and show times TBA. , Aphria, Inc., is a publicly ... of producing and supplying medical marijuana pursuant to the Marijuana for Medical Purposes Regulations ...
Breaking Medicine News(10 mins):